— Aurinia Pharmaceuticals (NASDAQ: AUPH) reported a third-quarter 2019 loss of $0.21 per share versus a loss of $0.15 per share expected.
— Revenue plunged by 39% to $230,000 versus $50,000 expected. The top line was hurt by nil contract revenue.
— Research and development expenses soared by 59% due to the manufacturing of voclosporin for commercial and investigational use. It also includes costs related to the Aurora 2 extension study and other expenses.
— As looking forward to results from the Aurora Phase 3 trial for kidney inflammation lupus nephritis by the end of this year, the company has been preparing for success by continuing to strengthen the Board.
— Looking ahead to 2020, and assuming positive results, Aurinia plans on submitting an NDA in the first half of 2020 and projects a commercial launch of voclosporin in early 2021 as a potential first-line treatment for lupus nephritis.
Most Popular
Infographic: Key highlights from Disney’s (DIS) Q2 2024 earnings results
The Walt Disney Company (NYSE: DIS) reported second quarter 2024 earnings results today. Revenues increased 1% year-over-year to $22.1 billion. Net loss attributable to The Walt Disney Company was $20
Earnings Preview: Alibaba likely to report mixed results for Q4
Alibaba Group Holding Limited (NYSE: BABA) will be reporting fourth-quarter 2024 financial results next week. Over the years, the e-commerce giant successfully diversified its business and emerged as a major
A look at Tyson Foods’ (TSN) expectations for the remainder of FY2024
Shares of Tyson Foods, Inc. (NYSE: TSN) fell over 7% on Monday. The stock has gained 7% year-to-date. The company delivered mixed results for the second quarter of 2024, with
